|
Method for preparing pectin gel of elevated part of willow herb |
||||||
IPC classes for russian patent Method for preparing pectin gel of elevated part of willow herb (RU 2510275):
Methods and compositions containing clonidine, applicable for treating postoperative pain / 2510263
Invention refers to an implantable drug depot applicable for the release, prevention or treatment of a postoperative pain in a patient in need thereof; the implantable drug depot contains a therapeutically effective amount of clonidine or its pharmaceutically acceptable salt and polymer; the drug depot is implantable into percutaneously for the release, prevention or treatment of postoperative paints; the drug depot can release: 1) approximately 5% approximately to 45% of clonidine or its pharmaceutically acceptable salt to total clonidine or its pharmaceutically acceptable salt as a part of the depot for a first period making up to 48 hours; 2) approximately 55% approximately to 95% of clonidine or its pharmaceutically acceptable salt to total clonidine or its pharmaceutically acceptable salt as a part of the depot for the following period making at least 3 days.
Agent, having antitumour, anticoagulant, wound-healing, anti-inflammatory and antioxidant activity, capacity to inhibit collagenase and angiotensin converting enzyme, and method for production thereof / 2509775
Invention relates to biotechnology and can be used to produce biologically active collagen peptides from marine hydrobionts. Patiria pectinifera starfish is dehydrated with 96% ethyl alcohol and then demineralised with 1-2 N solution of an inorganic acid with ratio of the raw material to inorganic acid of 1:(3-5) for 1-3 days. The demineralised raw material is washed from traces of acid and water-soluble impurities with distilled water, after which the material is hydrolysed with an alkali solution with ratio of raw material to the alkali solution of 1:(3-5) in order to remove non-collagen proteins and washed with distilled water at temperature of 2-4°C. The obtained starfish collagen shells are homogenised. The homogenate is diluted with distilled water; pH of the suspension is brought to a value equal to 8.0-8.5 with an alkali solution and hydrolysed with 1% collagenase solution with ratio of homogenate to enzyme of (100-200):1 and temperature of 30-40°C for 3-5 hours, pH 8.5-7.0. The enzyme is inactivated at 80-90°C for 10-15 minutes. The hydrolysate solution is filtered to remove non-hydrolysed collagen, subjected to ultra-filtration through a 30 kD membrane filter to remove the inactivated enzyme; the end product, having antitumour, anticoagulant, wound-healing, anti-inflammatory, antioxidant activity, capacity to inhibit collagenase and angiotensin converting enzyme and which is a complex of collagen peptides with a high-molecular weight component weighing 22-23 kD, is concentrated in a vacuum and lyophilised.
New therapeutic combinations of mirtazapine applicable in pain conditions / 2509560
Invention refers to pharmaceutics and represents a pharmaceutical combination for treating in pain conditions in the form of a solid dosage form for oral administration, characterised by the fact that it contains Mirtazapine 5 mg - 50 mg; Tizanidine 0.5 - 6 mg in ratio 20:1-5:1, and a pharmaceutically acceptable carrier.
Using peripheral dopamine receptor antagonists for preparing drugs increasing physical efficiency / 2508108
Invention refers to medicine, namely to using domperidone for preparing drugs increasing the physical efficiency in the mammals in need thereof. The drugs increasing the physical efficiency can be prepared in a single dosage form specified in a group consisting of a tablet, a capsule, a powder, a suspension or a syrup.
Long-term devices with polyurethane polymers for drug delivery and preparing them / 2508089
Invention refers to medicine. What is described is an implanted drug delivery device on the basis of polyurethane for the delivery of biologically active compounds at a constant speed for a long period of time, and a method for preparing it. The device is high biocompatible and bioresistant, and applicable as an implant for patients (human and animals) for the delivery of biologically active compounds to tissues and organs.
Method for improving transdermal permeability of therapeutic or cosmetic topical preparations, method for dermal administration of liquid xenon / 2506944
Invention refers to cosmetic and pharmaceutical industry and represents a method for improving the transdermal permeability of therapeutic or cosmetic topical preparations involving the dermal administration of 1.0 to 300.0 vol. % of liquid xenon as a part of an acceptable neutral carrier or a therapeutic or cosmetic preparation.
Combination for prevention, correction and therapy of pain related to neurodegeneration or associated with somatoform disorders / 2506077
Invention refers to chemical-pharmaceutical industry and represents a combination for the prevention, correction and therapy of pain related to neurodegeneration and/or associated with somatoform disorders, characterised by the fact that it consists of buspirone and doxepin taken in therapeutically effective amounts.
Method of treating osteoporosis and composition used therein / 2506070
Group of inventions refers to a storage-stable composition containing PTHrP (Parathyriod Hormone-Related Protein), and to a method for using a PTHrP analogue and PTHrP compositions declared in accordance with the present invention for bone mass gain and bone tissue improvement.
Agent for drug-induced correction of nitroxydergic disorders / 2505297
What is presented is using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide as an active drug base for the purpose of correcting the nitroxydergic malfunctions.
Oral compositions containing polyguanidine compounds, and methods for preparing and using them / 2505280
What is used is an oral composition containing a polyguanidine compound expressed by formula (I) and orally acceptable carrier. There are also presented: a method for the target delivery of the composition into the oral cavity, a method for inhibition of the development and prevention of dental caries, a method for the treatment of caries lesions.
Method for preparing drug microcapsules of cephalosporins in konjak gum in dioxane / 2509559
Invention refers to a method for preparing drug microcapsules of cephalosporins in konjak gum in dioxane. According to the declared method, a konjak gum solution in dioxane is added with a surfactant that is a cephalosporin powder pre-dissolved in ethanol, and with carbinol after cephalosporin forms an independent solid phase. The prepared microcapsule suspension is filtered, washed in acetone and dried in a drying oven.
Polysaccharides containing carboxyl functional groups substituted with hydrophobic alcohol derivative / 2504554
Disclosed is a polysaccharide containing carboxyl functional groups, one of which is substituted with a hydrophobic alcohol derivative. Also disclosed is a pharmaceutical composition containing one of the disclosed polysaccharides and one active ingredient.
Pharmaceutical composition in form of skin protection paste / 2503445
Invention refers to pharmaceutical composition in the form of a skin protection paste. The composition contains a film-forming agent representing poly(butyl methacrylate-co-methyl methacrylate), hydrocolloid, a filling agent, a softening agent and an alcoholic diluent in the certain proportions.
Method for preparing drug microcapsules of cephalosporin in konjak gum in carbon tetrachloride / 2502510
Invention refers to pharmaceutical industry, particularly to a method for preparing drug microcapsules of cephalosporin. The method for preparing drug microcapsules of cephalosporin consists in adding a konjak solution in carbon tetrachloride with a surfactant; a powder of cephalosporin is dissolved in water or ethanol and transferred into the konjak solution in carbon tetrachloride; once the antibiotic has formed an independent solid phase, carbinol and distilled water are added drop-by-drop; the prepared suspension of microcapsules is filtered, washed in acetone and dried; the process of microcapsules is carried out in the certain environment.
Complex of polysaccharide and hbp / 2498820
Present invention refers to medicine and described a complex prepared of a polysaccharide, particularly dextran, and a heparin-binding protein with the above polysaccharide being formed by (1,6) and/or (1,4) and/or (1,3) and/or (1,2) glycoside bonds and functionalised by at least one salt-forming or salt-transformed tryptophan derivative. The present invention also concerns a pharmaceutical composition containing the complex according to the invention.
Pharmaceutical formulation for treating infectious inflammatory gynaecological disorders and method for preparing it / 2498806
Invention refers to medicine and concerns a combined pharmaceutical composition having antibacterial activity. As an active substance, the composition contains a clindamycin salt or ester, a base which is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and a gelling polymer. A method of preparing the declared composition involves the fact that a solution of the clindamycin salt or ester in a part of the hydrophilic ingredient is added with the gelling polymer, then the emulsion prepared of a residual part of the hydrophilic ingredient, the hydrophobic ingredient and the emulsifier, and the prepared mixture is agitated until smooth.
Hyaluronic acid gels containing analgesic agents / 2496474
Invention refers to medicine. There are described soft tissue fillers, such as cutaneous and subcutaneous fillers based on hyaluronic acids and pharmaceutically acceptable salts thereof. What is described is a hyaluronic acid composition which contains a therapeutically effective amount of at least one analgesic agent, e.g., lidocaine, and additionally non-cross-linked hyaluronic acid. There are also described the methods for preparing the hyaluronic acid compositions.
Transpulmonary liposome for controlling drug delivery / 2493874
There are presented: a liposomal preparation for the pulmonary delivery, wherein the liposomes a surface of which is modified by at least one polymer specified in a group consisting of terminally hydrophobisated polyvinyl alcohols and chitosan, an encapsulated gene, a method for preparing and a method of treating a pulmonary tissue disease involving the stage of administering the above liposomal preparation into the patient's lung. It has been shown that the liposome modified by terminally hydrophobisated polyvinyl alcohol may be kept on the pulmonary tissue surface for a long time.
Production of rapidly dissolved/short lived films containing large number of active substances / 2492854
Invention refers to pharmaceutics, namely it represents a rapidly dissolved or short lived preparation of a film containing a large number (i.e., at least about 40%) of the active material(s), and methods for preparing it. The invention represents a rapidly dissolved or short lived dry film for active substance delivery, containing an active substance, one water-soluble polymer specified in pullulan, hydroxypropylmethyl cellulose, polyvinylpyrrolidone and mixtures thereof, and other optional ingredients.
Method for preparing drug microcapsules of cephalosporin in konjac gum in chloroform / 2491939
Invention refers to microcapsulation of drug preparations of cephalosporins referred to β-lactam antibiotics in konjac gum by physical-chemical precipitation in a non-solvent. Konjac gum is used as a microcapsule membrane. The microcapsules are prepared by physical-chemical precipitation in the non-solvent with using two precipitation agents - carbinol and chloroform. The process of microcapsules is carried out at 25°C with no special equipment required.
Oral composition / 2510262
Group of inventions refers to medicine, namely to dentistry, and may be used as an oral composition for controlling an oral sweetener release. The above composition contains a polymer attached to the sweetener by a breakable link comprising a covalent bond, an ester bond or an amide bond. The breakable link is breakable in the oral cavity to release the sweetener. Said polymer is a polymer adhered to the mucosa and specified in methyl vinyl ether/maleic anhydride copolymer with polymer found in the amount of 0.001% to 10%. The sweetener is specified in dextrose, saccharose, maltose, dextrin, dried invert suger, mannose, xylose, ribose, fructose, lexulose, galactose, corn syrup, partially hydrolysed starch, sorbitol, mannitol, isomalt, aspartame, neotame, saccharine and its salts, sucralose, the sweeteners on the basis of dipeptides, cyclamates, dihydrochalcone with the sweetener content making 0.005% to 5%. What is also presented is a portable dispenser, a method for preparing the oral composition, a method for controlling the sweetener in the oral cavity, and using the polymer.
|
FIELD: medicine. SUBSTANCE: invention refers to a method for preparing a pectin gel of an elevated part of willow herb. The declared method enables dissolving pre-recovered pectin from the elevated part of willow herb in water, cooling and applying onto a frozen chitosan solution and further gel formation. EFFECT: invention enables preparing a degradable biomaterial possessing the antimicrobial activity on Escherichia coli and Staphylococcus aureus cells. 1 tbl, 1 ex
The invention relates to the medical industry, namely to obtain pectin preparations used in the manufacture of a prophylactic and therapeutic tools. Gel-forming ability of pectin depends on many factors, including the degree of methylethylamine, localization ester metal groups, pH, concentration of the biopolymer, the concentration of calcium ions, ionic strength of the solution, temperature. We can distinguish the following main directions of the use of gels in Biomedicine: designing systems for targeted drug delivery, creating selective chelators, creating materials for tissue engineering and surgery. As gelling polymers are widely used polysaccharides of animal, bacterial and plant origin, such as cellulose, dextran, chitosan, and their derivatives. It is established that pectic polysaccharides have several advantages over other gel-forming biopolymers. Unlike biopolymers animal and microbial origin pectins are characterized by higher biological security. Usually ways to obtain gels based on plant polysaccharides include the following stages: receiving from the source plant material polysaccharide, purification of the polysaccharide or the modification of its properties, rest is increased polysaccharide in the solution under stirring, the formation of a gel, drying. There are several technological methods, improving physiological and technological properties of the resulting gels. Thisthe improved composition of the gel exclusion from the use of toxic reagents; the expansion of raw materials sources of pectin. A method of obtaining single-component gel on the basis of pectin by increasing its gelling ability, reaching the amidation of pectin by passing gaseous ammonia through a pectin solution (EN12399301, A23L 1/0524, 2010). The disadvantage of this process is the necessity of using large amounts of ammonia, as well as the use of commercial samples of pectin that does not have a pronounced physiological activity. Another way to obtain a gel-based chitosan (EN12099352, IPC SW 37/08, 1997) consists in the reaction of chitosan with glutaraldehyde in acetate buffer at pH 3.5 to 5.5, ionic strength of a solution of 0.1-0.5 and the molar ratio of glutaric aldehyde: chitosan 1:6-15 with subsequent recovery of the reaction product with sodium borohydride allocation of hydrogenerators. It is necessary to use a large number of chemicals. Way to get the gel on the basis of modified pectin by it in the pre-treatment solution of metal chloride (RU 12113221, A61K 9/50, 1998), involves the use of alkali for the process of gelation, which reduces the ecological purity of the product. The disadvantage of the gel composition for the treatment of RAS (RU12384338, A61K 31/715, OR 17/02, 2010) is the use of high-purity beet pectin, not possessing physiological activity, and synthetic substances, the antiseptic chlorhexidine. The closest way to obtain pectin gel to the invention is a method including dissolving purified and powdered sugar beet pectin in distilled water at a temperature of 20-30°C and stirring until smooth within 20-30 minutes the resulting solution of pectin thickness 2.0-2.5 mm is applied on the PTFE surface and dried at a temperature of 20-50°C for 24-48 hours (EN12342955, A61L 15/28, A61L 15/44, A61F 13/15, A23L 1/0524, 2009). The disadvantage of this method is use to get gel purified beet pectin, not possessing physiological activity, and low strength of the gel and prolonged drying at relatively high temperatures. The aim of the present invention is to increase physical activity and improve the technological properties of the gel on the basis of pectin. The technical result is t from the use of the invention in that, as a result of the use of the method obtained degradable biomaterial, has antimicrobial activity against cells of Escherichia coli and Staphylococcus aureus. This result is achieved by the fact that to obtain the gel we use the pectin isolated from the aerial parts of fireweed herb with antibacterial activity against strains of Escherichia coli and Staphylococcus aureus. To improve the strength characteristics of the gel coating is provided on chitosan matrix, forming with pectin complex through ionotropic gelation. The method of producing gel-based pectin from the aerial parts of fireweed herb involves the dissolution of pre-allocated pectin from the aerial parts of fireweed herb in water and then cooled and applied to a pre-frozen solution of chitosan and the subsequent formation of a gel; the dissolution of the pectin is carried out by heating to 70°C to obtain a 0.4%aqueous solution, followed by cooling of a solution of pectin occurs to a temperature of +4±1°C cooled solution of pectin is applied to frozen at -18±1°C for 40 minutes with 5%chitosan solution obtained preliminary dissolution of chitosan acetate buffer (pH=3,6) at 70°C with the addition of calcium chloride, the formation of a gel occurs within 6-8 hours at room temperature the re. An example of the method. 0.4 g of pectin, previously isolated from the aerial parts of fireweed herb and lyophilized, dissolved in 100 ml of distilled water by heating to 70°C. 2.5 g of chitosan was dissolved in 50 ml of acetate buffer (pH 3,6) when heated to 70°C and was added 0.27 g of calcium chloride. A solution of chitosan was poured into the form and frozen at -18±1°C for 40 minutes. The solution of pectin was cooled to a temperature of +4±1°C. the frozen solution of chitosan poured into a chilled solution of pectin in a volume ratio of 1:1. The gel formation occurred within 6-8 hours at room temperature. Characteristics of the resulting gel is shown in the table.
Thus, the obtained data testify that the invention allows to obtain a gel based on physiologically active polysaccharide pectin fireweed herb with antimicrobial activity against strains of Escherichia coli and Staphylococcus aureus, while by using ionotropic gelation with chitosan reduced the formation of gel and improve its technological characteristics. The method of producing gel-based pectin from the aerial parts of fireweed herb, including the dissolution of pre-allocated pectin from the aerial parts of fireweed herb in water and then cooled and applied to a pre-frozen solution of chitosan and the subsequent formation of a gel; the dissolution of the pectin is carried out by heating to 70°C to obtain a 0.4%aqueous solution, followed by cooling of a solution of pectin occurs to a temperature of +4±1°C cooled solution of pectin is applied to frozen at -18±1°C for 40 min 5%solution of chitosan, obtained preliminary dissolution of chitosan in acetate buffer (pH=3,6) at 70°C with the addition of calcium chloride, formirovaniya occurs within 6-8 h at room temperature.
|
© 2013-2014 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English. |